The Multiple Sclerosis trial for the disease modifying drug called CDP323 is entering into its fourth month. To date we have dosed 33 volunteers and the response has been very positive. We are keen to fill the last few limited places for the study before Christmas.
We are pleased to announce we have taken all the constructive feedback from our participants and made improvements wherever was suggested regarding the trial. Our wards have been upgraded and are now more suitable for people with disabilities.
We have had very positive feedback from some of our volunteers: "The money is a major attraction for the trial but I have struggled before with DMD by injection and therefore this is a great opportunity for me as well as many other people for an oral drug. During my in-house period I was part of a very co-hesive group, and I made many friends and we spent a lot of time discussing how MS effects us and our families. This is a very good way of advancing clinical knowledge." Carol Carey, London.
Another positive participant, Christopher P McNamara, commented the following: "If we are to have new and better treatments for MS then people with MS will have to step up and be willing to participate in trials. It's only for a few weeks and I was happy to do so. I used the time to catch up on my reading and chat with the other volunteers mostly. Although a diverse bunch, we had MS in common, and it was nice to chat, compare experiences and we're all going to stay in touch now that the trial is over."
Many of our volunteers have taken a liking to one of our specialist staff Bibi Jilka. Bibi says "I feel very privileged to be a part of such an important trial to help in the fight against Multiple Sclerosis. The people have been wonderful, it makes my job all worthwhile!"
If you are not selected to take part in this trial you can still aid in the
research process and earn extra money by recommending a friend.
Recommend a friend successfully and once they have completed the trial you will
receive a very nice thank you from us.
See the website for details.
Richmond Pharmacology would like to take this time to thank all the people who have been supportive and taken a keen interest in the clinical trial for CDP323.
A special thanks to the staff of the MS therapy centres who have always made us feel very welcome when presenting our information to their members.